# Healthcare SAMD: Regulatory PM Excellence

## Redesigning FDA-Regulated Onboarding Under Pressure

**Client:** Fortune 500 Pharmaceutical Company  
**Duration:** 10 months  
**Role:** Product Manager  
**Domain:** Healthcare IoT, SAMD Class II Medical Device  
**Regulatory Context:** FDA 21 CFR Part 11 Compliance

---

## Executive Summary

When the pharmaceutical company's insulin dose recommendation app faced patient drop-offs during a critical 3,000-patient marketing campaign, the stakes were high: **$2 million in penalties** if the FDA-approved app wasn't ready on time. The 24-step onboarding flow was overwhelming patients, especially those already enrolled through marketing with pre-existing data.

As Product Manager for this **SAMD Class II medical device**, I led a high-stakes redesign under FDA regulatory constraints where every screen change required Human Factor studies and compliance validation. By identifying redundant data collection in the marketing cohort, I **reduced 24 screens to 5** for pre-existing patients—but stakeholders initially resisted due to compliance concerns.

**The outcome:** 3,000 users onboarded in **8 weeks instead of 24 weeks** (3x faster), completion rates jumping from **72% to 94%**, the $2M penalty prevented, and **zero FDA violations** across 8 audits. This case study reveals what regulatory product management looks like when patient safety, business pressure, and compliance rigor collide.

---

## Context: Life-Critical Product Development

### The Product
The client's SAMD (Software as a Medical Device) platform consisted of two interconnected apps:
1. **Insulin Dose Recommendation Engine** (SAMD Class II): Bluetooth-enabled glucose monitor + FDA-regulated dose calculator providing life-critical insulin recommendations
2. **Medication Adherence Onboarding**: Mobile app guiding patients through setup, profile creation, device pairing, and treatment plan configuration

Unlike typical consumer apps where bugs are fixable with hotfixes, **every feature change required Human Factor studies**, FDA documentation, and formal validation. A poorly designed flow didn't just hurt metrics—it could compromise patient safety.

### The Business Context
The pharmaceutical company was launching an aggressive marketing campaign targeting **3,000 Type 1 Diabetes patients** who had shown interest through pre-enrollment forms, call center interactions, and healthcare provider referrals. These patients had already provided:
- Medical history and current medications
- Insurance information and provider details  
- Contact preferences and communication consent
- Basic demographic and lifestyle data

Yet the app's standard onboarding flow **asked for all this information again** across 24 separate screens—frustrating patients who'd already shared it and causing significant drop-offs before reaching the core dose recommendation features.

### The Regulatory Challenge
This wasn't a typical "move fast and break things" product environment:

- **FDA 21 CFR Part 11 Compliance**: All software changes required documented validation showing patient safety wasn't compromised
- **Human Factor Studies**: Every 4 sprints (8 weeks), we conducted formal usability testing with Type 1 Diabetes patients to validate screen flows, error messaging, and safety warnings
- **Audit Trail Requirements**: Every patient interaction, data input, and system calculation needed to be logged and traceable for FDA audits
- **Change Control Rigor**: Screen redesigns required formal review by medical affairs, legal, compliance, and engineering—not just PM approval

When I joined, the 24-step onboarding flow had been designed conservatively with full data collection for *all* patient types, treating everyone as a cold acquisition despite marketing having warmer leads.

### The Stakes
Two pressures converged:
1. **FDA Approval Timeline**: The dose recommendation algorithm's FDA clearance was progressing faster than expected, with approval projected in 16 weeks instead of 24
2. **Penalty Clause**: The client's contract with the marketing vendor included a **$2 million penalty** if the app wasn't ready to onboard the 3,000 pre-enrolled patients when FDA approval came through

Leadership's message was clear: **Speed up onboarding without violating compliance**—no small ask in a regulated medical device environment.

---

## Discovery: Finding Redundancy in Patient Data Flows

### The Drop-Off Problem
I started by analyzing where patients abandoned the onboarding:

- **Screens 1-8 (Profile Setup)**: 15% drop-off rate—patients frustrated by re-entering data they'd already provided to marketing
- **Screens 9-16 (Medical History)**: 28% drop-off—redundant questions about medications, allergies, provider info already captured
- **Screens 17-24 (Device Pairing)**: 12% drop-off—confusion over Bluetooth setup and sensor calibration

**Total completion rate: 72%** across all patient cohorts (cold, warm, and pre-enrolled).

The pattern was obvious: **Pre-enrolled marketing patients dropped off earlier** (Screens 1-8) compared to cold acquisitions who expected to fill out extensive forms. They'd already done the work.

### Stakeholder Interviews
I conducted 12 interviews across:
- **Medical Affairs SMEs** (3 interviews): Confirmed that for pre-enrolled patients with verified data from marketing, re-asking was clinically unnecessary—as long as we validated data integrity
- **Compliance Lead** (2 interviews): Nervous about "skipping" screens but acknowledged that *different flows for different cohorts* was FDA-compliant if documented properly  
- **Marketing Team** (4 interviews): Confirmed they collected 18 of the 24 data points through pre-enrollment forms, call center scripts, and provider referrals
- **Engineering Lead** (3 interviews): Confirmed feasibility of dynamic flows based on patient source (marketing vs. organic) with proper backend flags

The insight: **We didn't need to reduce 24 screens universally—just for the 3,000 marketing cohort where we already had validated data.**

### Validation with Patients
I shadowed 6 Type 1 Diabetes patients during onboarding (part of our regular Human Factor study):
- **5 out of 6** expressed frustration when asked to re-enter information they'd "already told someone"
- **4 out of 6** abandoned mid-flow and later resumed after support calls
- **3 out of 6** explicitly said, "Why are you asking me this again?"

The patient experience validated the data: **redundancy wasn't just inefficient, it eroded trust**.

---

## Strategy: Cohort-Specific Redesign

### The Proposal
Instead of redesigning the entire 24-screen flow (risky and time-consuming for all patient types), I proposed:

**Create a streamlined 5-screen flow for pre-enrolled marketing patients:**
1. **Welcome + Identity Verification** (confirm phone/email)
2. **Data Review & Consent** (show pre-filled profile, let patients edit if needed)
3. **Device Pairing Instructions** (Bluetooth sensor setup with visual guides)
4. **Treatment Plan Selection** (choose insulin regimen with doctor's input)
5. **Safety Acknowledgment** (confirm understanding of dose recommendations as guidance, not prescription)

This approach:
- ✅ Eliminated redundant data entry for the 3,000 marketing patients
- ✅ Preserved the full 24-screen flow for cold acquisitions (no risk to organic growth)
- ✅ Maintained FDA compliance by documenting cohort-specific flows as "alternate paths for verified patients"
- ✅ Could be built in 8 weeks with existing backend architecture

### Initial Stakeholder Resistance
My first proposal was actually **6 screens**, but the client's medical affairs team pushed back hard:

**Client's Concern:** "We need patients to actively confirm medical history—pre-filled data might have errors from marketing's intake process. What if someone's allergy information is wrong and they get a bad dose recommendation?"

**Their Counter-Proposal:** "Keep 12 screens minimum—add confirmation screens for medications, allergies, provider info, and insurance."

This was a pivotal negotiation moment. Compliance teams in regulated environments default to *caution over speed*, which is understandable when patient safety is at stake.

### The Negotiation
I went back to marketing and compliance with a data-driven counter:

**Evidence I Gathered:**
1. **Marketing's Data Quality Audit**: Reviewed 100 pre-enrolled patient records—98% accuracy rate on medical data (verified against pharmacy records and provider EHRs)
2. **Regulatory Precedent**: Found 3 other FDA-approved SAMD apps (competitors) that used pre-filled profiles with single-screen confirmation instead of multi-step re-entry
3. **Patient Safety Protocol**: Proposed adding **inline validation** on Screen 2 (Data Review) where patients explicitly click checkboxes confirming "My allergy information is correct" and "My current medications are accurate"—creating an audit trail without full re-entry

**The Argument:**
> "If we trust marketing's data quality (98% accurate), then asking patients to re-enter creates *more* risk—they might mistype or skip fields out of frustration. Pre-filled data with **explicit confirmation** gives us the same compliance coverage with better UX and faster time-to-value."

After **3 rounds of negotiation** over 2 weeks, stakeholders agreed to **5 screens** with enhanced inline confirmations on Screen 2. The key was showing that patient safety wasn't compromised—just the *method* of data validation was more efficient.

---

## Execution: Building Under Regulatory Constraints

### Cross-Timezone Coordination
The team was split:
- **US Side**: Product (me), Medical Affairs SMEs, Compliance Lead, Client Stakeholders (EST)
- **India Side**: Engineering (8 developers), QA (4 testers), DevOps (2) (IST—10.5-hour time difference)

To keep velocity:
- **Daily Sync at 8 AM EST / 6:30 PM IST**: 30-minute standup covering blockers, compliance questions, and design decisions
- **Async Design Reviews**: I recorded Loom videos walking through wireframes, inline validations, and error flows—engineers watched overnight and flagged concerns via Slack before our sync
- **Compliance Check-ins Every Sprint**: Medical Affairs SME joined sprint demos to validate that new flows met FDA Human Factor guidelines

The time zone gap was actually helpful for compliance—US stakeholders reviewed designs during their workday, India engineering built overnight, and I reconciled feedback the next morning before the next build cycle.

### Human Factor Studies Every 4 Sprints
FDA's Human Factor guidance required us to test with **real Type 1 Diabetes patients** at regular intervals:

**Sprint 2 (Week 4)**: Tested wireframes of 5-screen flow with 8 patients
- **Finding**: Patients loved the speed but were confused by "Data Review" screen—too much text, unclear what to confirm
- **Action**: Redesigned Screen 2 with collapsible sections (Profile, Medical, Insurance) and explicit checkboxes per category

**Sprint 4 (Week 8)**: Tested high-fidelity prototype with 10 patients
- **Finding**: Bluetooth pairing instructions (Screen 3) had 40% failure rate—patients didn't know which sensor model they had
- **Action**: Added visual device selector at start of Screen 3 (photos of 3 sensor models) to auto-load correct pairing steps

**Sprint 6 (Week 12)**: Tested beta build with 12 patients in production-like environment
- **Finding**: Safety Acknowledgment (Screen 5) felt like "legal speak"—patients rushed through without reading
- **Action**: Broke into 3 sub-screens with scenario-based questions ("If your glucose is 250 mg/dL and the app suggests 4 units, what should you do?") to confirm comprehension

Each study added 1-2 weeks to the timeline, but **skipping them wasn't an option**—FDA audits would scrutinize whether we validated patient understanding of life-critical features.

### The Config Tool (And My Biggest Mistake)
To avoid dev bottlenecks, we built a **content management system** for non-engineers to update:
- Screen copy and translations (English, Spanish)
- Inline help tooltips and safety warnings
- Visual assets (sensor photos, pairing diagrams)

This let Medical Affairs update safety language without engineering tickets—a huge velocity win.

**The Incident:**  
During Sprint 5, I was testing the config tool in our staging environment and accidentally **refreshed the entire content library** instead of a single screen's copy. The tool had a poorly labeled "Reset All" button next to "Revert Changes," and I clicked the wrong one.

**Impact:**  
All screens reverted to default placeholder text ("Lorem ipsum"), broke translations, and replaced safety warnings with debug strings. The staging build was unusable for the next day's client demo.

**What I Did:**
1. **Owned it immediately**: Called the engineering lead (11 PM IST) and compliance lead (8 AM EST) to disclose the mistake
2. **Worked overnight**: Manually restored content from our last backup (6 hours), re-imported translations (2 hours), and validated every screen against our compliance documentation (3 hours)
3. **Fixed by morning**: Had a working staging build 14 hours later before the client saw anything broken
4. **Disclosed to client transparently**: Once it was sorted, informed the client's program manager about the incident, what caused it, and the process improvements we'd implement (adding confirmation modals to destructive actions, better button labels)

**Client's Reaction:**  
Initially uncomfortable ("How did this happen?"), but appreciated the **ownership and speed of resolution**. The compliance lead later told me this built trust—many vendors try to hide mistakes, but we showed we could handle crises responsibly.

**Lesson:** In regulated environments, **honesty after a mistake matters more than perfection**. Hiding issues can turn minor incidents into audit findings.

---

## Results: 3x Faster Onboarding with Zero FDA Violations

### Launch Metrics
We deployed the 5-screen flow to the 3,000 pre-enrolled marketing patients in **Week 16** (2 weeks before FDA approval):

**Onboarding Completion:**
- **Before Redesign** (24-screen flow for organic patients): 72% completion rate over 24 weeks average
- **After Redesign** (5-screen flow for marketing cohort): **94% completion rate in 8 weeks**

**Speed to Value:**
- **Original Timeline**: 24 weeks to onboard 3,000 patients (FDA approval expected Week 24)
- **Actual Result**: 3,000 patients onboarded in **8 weeks** (3x faster), 16 weeks before FDA approval deadline
- **Penalty Avoided**: $2M penalty clause nullified by hitting target early

**Patient Satisfaction (Post-Onboarding Survey, n=450):**
- 89% rated onboarding experience as "Easy" or "Very Easy" (vs. 64% for 24-screen flow)
- 76% appreciated pre-filled data: "Felt like they already knew me"
- 12% still wanted to review medical data manually (we added an "Edit My Profile" option post-launch)

### Compliance & Audit Performance
**FDA Audit Trail:**
- **8 internal compliance audits** across 10 months: Zero findings related to the redesigned flow
- **2 FDA on-site inspections**: Reviewers praised cohort-specific documentation as "well-substantiated alternate path design"
- **Human Factor Studies**: All 3 studies (Sprints 2, 4, 6) passed FDA's usability guidance criteria

**Data Quality Validation:**
- Post-launch audit of 500 pre-enrolled patients: **99.2% accuracy** on pre-filled medical data (higher than the 98% pre-launch estimate)
- 3 patients reported allergy mismatches (0.6%)—caught during inline confirmation on Screen 2 before reaching dose recommendations

The result: **No patient safety incidents related to onboarding data** across 3,000 users in the first 6 months.

### My Role Completion
I rolled off the project in **Week 24** after:
- Successfully onboarding 3,000 marketing patients (primary KPI met)
- Preventing $2M penalty (business goal achieved)
- Passing 2 FDA inspections with zero findings (compliance goal achieved)

The client transitioned to a sustaining PM for ongoing feature development (device compatibility updates, expanded cohort support). My mandate was the high-stakes redesign under pressure—mission accomplished.

---

## What Didn't Work: The Messy Middle

### 1. The First Redesign Attempt (6 Screens → Rejected)
**What I Proposed:**  
Initial redesign included 6 screens:
1. Welcome
2. Identity Verification
3. Data Review (Medical)
4. Data Review (Insurance)
5. Device Pairing
6. Safety Acknowledgment

**Why It Failed:**  
The client's medical affairs team pushed back: "Two separate data review screens (3 and 4) feel like we're *still* asking too much. Why not combine them into one comprehensive review?"

Meanwhile, compliance wanted **12 screens minimum** (essentially keeping half the original flow).

**The Problem:**  
I was trying to split the difference between efficiency and caution, but ended up with a design that satisfied *nobody*:
- Too long for patients who wanted speed
- Too short for stakeholders who wanted explicit confirmations

**What I Learned:**  
In stakeholder negotiations, **propose your ideal state first** (5 screens), not a compromise. Let *them* push you toward middle ground. I wasted 2 weeks negotiating from 6 screens when I should've started at 5 and defended it with data.

### 2. End-Stage Feedback Instead of Continuous Validation
**What Happened:**  
I designed the 5-screen flow over 3 weeks, got engineering to build a high-fidelity prototype, then presented it to Medical Affairs SMEs in Sprint 2 for feedback.

**Why It Was Risky:**  
By waiting until a polished prototype, I'd already locked in:
- Information architecture (which data on which screen)
- Inline validation patterns (checkboxes vs. dropdowns)
- Error messaging and safety warnings

When SMEs flagged concerns (e.g., "Allergies need to be more prominent on Screen 2"), it required **rework of entire screen layouts** instead of quick wireframe tweaks.

**What I Should've Done:**  
Validated with Medical Affairs and Compliance **every week during design** via:
- Low-fidelity wireframes in Week 1 (validate information architecture)
- Content drafts in Week 2 (validate safety language)
- High-fidelity mockups in Week 3 (validate visual hierarchy)

**Impact:**  
The end-stage feedback approach added **2 extra weeks** to Sprint 2 for redesign. If I'd validated incrementally, we could've caught issues earlier with lower rework cost.

**Lesson:** In regulated environments, **compliance stakeholders should be co-designers, not reviewers**. Embed them in weekly design iterations, not sprint-end demos.

### 3. Underestimating Human Factor Study Iteration
**What I Assumed:**  
Human Factor studies would validate our designs with minor tweaks (e.g., button labels, color contrast for accessibility).

**Reality:**  
Each study uncovered **fundamental usability issues**:
- Sprint 2: Screen 2 overwhelmed patients (led to full redesign with collapsible sections)
- Sprint 4: Screen 3 Bluetooth pairing failed 40% of the time (added device selector)
- Sprint 6: Safety Acknowledgment felt like "legal speak" (broke into 3 sub-screens with scenario questions)

**Why This Mattered:**  
I'd planned 1 week per study for minor polish, but each required **2-3 weeks of redesign + re-testing**. This pushed our timeline from 12 weeks to 16 weeks.

**What I Learned:**  
In SAMD product development, **budget 3x time for usability findings**. Patients interacting with life-critical features will surface edge cases you can't predict in internal reviews. Plan for iteration, not validation.

---

## Key Takeaways: Regulatory PM in High-Stakes Environments

### 1. Honesty and Ownership in Crises
**The Principle:**  
When things break (and they will), **own the mistake immediately, fix it fast, then disclose transparently**. Hiding issues in regulated environments turns operational incidents into compliance violations.

**How I Applied It:**  
During the config tool incident, I could've:
- ❌ Blamed the poor UX of the "Reset All" button (deflect responsibility)
- ❌ Restored from backup *without* telling the client (hide the mistake)
- ❌ Delayed disclosure until the next sprint review (minimize visibility)

Instead, I:
- ✅ Called stakeholders immediately (even at 11 PM IST for engineering)
- ✅ Worked overnight to fix before it impacted the client demo
- ✅ Disclosed the incident *after* it was resolved, along with process improvements

**Client's Feedback:**  
"We work with a lot of vendors who try to cover up mistakes. You showed us you can handle pressure and prioritize patient safety over looking good. That's the partnership we need."

**For Other PMs:**  
In healthcare, finance, or any regulated domain—**your response to failure matters more than avoiding failure**. Build trust through crisis management, not perfection.

### 2. Compliance Stakeholders as Co-Designers, Not Gatekeepers
**The Mistake I Made:**  
Treating Medical Affairs, Compliance, and Legal as **reviewers at the end of design sprints** instead of **collaborators during design sprints**.

**What I Should've Done:**  
- **Weekly Design Reviews** with compliance (not bi-weekly sprint demos)
- **Shared Figma/Miro boards** where SMEs could comment on wireframes in real-time
- **Pre-sprint kick-offs** to align on regulatory constraints before design started

**Impact of Shift:**  
When I started inviting the Compliance Lead to weekly design sessions in Sprint 3, we caught issues like:
- "This error message doesn't meet FDA's plain language guidelines" (fixed in wireframes, not after build)
- "Allergy confirmation needs to be on a separate screen per 21 CFR Part 11" (pivoted information architecture early)

**Time Saved:** ~3 weeks of rework across Sprints 4-6 by validating compliance *during* design instead of *after* build.

**For Other PMs:**  
If your domain has regulatory constraints (FDA, HIPAA, SOC 2, GDPR), **embed compliance stakeholders in your design process from Day 1**. Treat them as co-designers who help you navigate constraints, not gatekeepers who slow you down.

### 3. Iterative Validation > Big Bang Launches in Regulated Products
**The Temptation:**  
Build the perfect 5-screen flow, test it once in a Human Factor study, launch to 3,000 patients.

**Why That's Risky:**  
In SAMD products, **you don't get do-overs**. If a patient doesn't understand the Safety Acknowledgment screen (Screen 5) and misuses dose recommendations, it's a patient safety incident—not a "bug we'll fix in the next sprint."

**What Worked:**  
- **Sprint 2:** Test wireframes with 8 patients (validate information architecture)
- **Sprint 4:** Test high-fidelity prototype with 10 patients (validate interaction patterns)
- **Sprint 6:** Test beta build with 12 patients in production-like environment (validate real-world comprehension)

Each layer of validation added **1-2 weeks**, but caught critical usability issues *before* FDA scrutiny.

**For Other PMs:**  
In life-critical products (medical devices, automotive software, industrial IoT), **budget 3x your typical usability testing timeline**. Iterate slowly with real users, not internal stakeholders. Patient safety > speed.

### 4. Data Quality Beats Caution in Stakeholder Negotiations
**The Dynamic:**  
Compliance teams in regulated environments default to **maximum caution** because the downside of failure (FDA warning letter, patient harm) outweighs the upside of efficiency (faster onboarding).

**How to Shift the Conversation:**  
Instead of arguing "Trust me, it'll be fine," I brought:
- **Marketing's Data Quality Audit**: 98% accuracy on pre-filled medical data (later validated at 99.2% post-launch)
- **Regulatory Precedent**: 3 competitor SAMD apps with similar pre-filled flows that passed FDA approval
- **Inline Validation Design**: Explicit checkboxes on Screen 2 creating audit trails for patient confirmations

**What Changed:**  
Compliance Lead went from "We need 12 screens minimum" to "If we have 99% data accuracy and explicit confirmations, 5 screens is defensible in an FDA audit."

**For Other PMs:**  
In risk-averse environments, **replace opinion with evidence**. Compliance stakeholders aren't unreasonable—they're protecting against worst-case scenarios. Show them the data that makes those scenarios unlikely.

### 5. Vigilance and Smart Learning in Cross-Functional Chaos
**The Reality:**  
Regulatory PM work is **constant context-switching**:
- Morning: Design review with Medical Affairs SMEs
- Midday: Sprint planning with India engineering (6:30 PM their time)
- Afternoon: Human Factor study debrief with QA
- Evening: Compliance documentation updates for FDA audit trail

It's easy to miss details (like the "Reset All" button incident) when you're juggling 8 stakeholder groups.

**What Worked:**  
- **Weekly Checklist Review**: Every Friday, I reviewed a checklist of compliance requirements (audit trails, Human Factor docs, safety validations) to catch gaps before they became blockers
- **Delegation to Specialists**: I didn't try to become an FDA expert—I leaned on Medical Affairs SMEs for regulatory interpretation and focused on translating their guidance into product decisions
- **Learning in Public**: When I didn't know something (e.g., "What's the CFR Part 11 requirement for electronic signatures?"), I asked in team channels instead of researching solo—faster answers, shared learning

**For Other PMs:**  
In complex domains, **you can't be the expert on everything**. Build a network of specialists, ask questions publicly, and stay vigilant on the details that matter (compliance checkpoints, patient safety validations). Learn smartly by leveraging your team's collective knowledge.

---

## Reflections: What Regulatory PM Taught Me

This project was one of the most stressful and rewarding experiences of my career—handling a **$2M penalty risk** while navigating FDA compliance, stakeholder negotiations, cross-timezone coordination, and my own config tool mistake.

**What I Loved:**
- **High-Stakes Problem-Solving**: Every decision had real consequences (patient safety, business penalties, FDA scrutiny). The pressure forced clarity and discipline.
- **Stakeholder Mastery**: Negotiating from 6 screens to 5 with compliance-averse stakeholders taught me how to use data, precedent, and empathy to move risk-averse partners.
- **Iterative Rigor**: Human Factor studies every 4 sprints felt slow at first, but catching usability issues early saved us from post-launch patient safety incidents.

**What I'd Do Differently:**
- **Embed compliance in design from Week 1** (not Sprint 2)
- **Propose 5 screens initially** (not 6 as a compromise)
- **Budget 3x time for Human Factor studies** (plan for iteration, not validation)

**The Bigger Lesson:**  
Regulatory PM isn't about *avoiding* constraints—it's about **designing within them creatively**. The 5-screen flow wasn't a compromise between speed and compliance; it was a *better product* because we had to justify every screen's necessity. Constraints forced us to eliminate redundancy, prioritize patient experience, and build with precision.

If you're a PM entering regulated healthcare, fintech, or automotive software: **embrace the constraints**. They'll make you a more disciplined, evidence-driven, and empathetic product leader.

---

## Appendix: Metrics Summary

| Metric | Before Redesign | After Redesign | Change |
|--------|----------------|----------------|---------|
| **Onboarding Completion Rate** | 72% | 94% | +22 pts |
| **Time to Onboard 3,000 Patients** | 24 weeks | 8 weeks | **3x faster** |
| **Patient Satisfaction (Post-Onboarding)** | 64% "Easy/Very Easy" | 89% "Easy/Very Easy" | +25 pts |
| **Screen Count (Marketing Cohort)** | 24 screens | 5 screens | **-79% reduction** |
| **FDA Audit Findings** | N/A (baseline) | 0 findings | **Zero violations** |
| **Data Quality (Pre-Filled Info)** | 98% accurate (pre-launch) | 99.2% accurate (post-launch) | +1.2 pts |
| **Penalty Avoided** | $2M at risk | $0 penalty | **$2M saved** |

---

**Want to discuss regulated product development, stakeholder negotiation under pressure, or FDA compliance strategies?**  
[Let's connect.](/#contact)
